Last Updated : April 24, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tecentriq | Atezolizumab | Withdrawn | ||||
Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | ||
Tecfidera | Dimethyl fumarate | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
Technivie | Ombitasvir/ paritaprevir/ ritonavir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Active | |||
Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete |